Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $20.00.

ALT has been the subject of a number of research reports. UBS Group initiated coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Thursday, November 14th.

Altimmune Trading Down 6.7 %

Shares of ALT opened at $8.40 on Friday. The firm has a market cap of $597.45 million, a PE ratio of -5.42 and a beta of 0.15. The firm has a fifty day simple moving average of $7.81 and a two-hundred day simple moving average of $7.08. Altimmune has a 1-year low of $5.28 and a 1-year high of $14.84.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the prior year, the firm posted ($0.39) earnings per share. As a group, research analysts forecast that Altimmune will post -1.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Altimmune

A number of hedge funds have recently modified their holdings of ALT. Geode Capital Management LLC boosted its holdings in Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after buying an additional 74,194 shares during the period. Bellevue Group AG boosted its holdings in Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after buying an additional 263,660 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after buying an additional 335,444 shares during the period. BBR Partners LLC boosted its holdings in Altimmune by 4.5% in the 2nd quarter. BBR Partners LLC now owns 374,784 shares of the company’s stock worth $2,492,000 after buying an additional 16,271 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Altimmune by 542.8% in the 2nd quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after buying an additional 214,968 shares during the period. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.